Southlake, TX based OncoNano Medicine is harnessing nanotechnology to identify and target cancer - a lead program hits the STING pathway

blonca9
Oct 29, 2024
1 min read

CFO Matthew Head describes the company's ON-BOARD platform and how they are not only developing therapeutics, but also an imaging product that has breakthrough designation.

Brought to you by

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Southlake, TX based OncoNano Medicine is harnessing nanotechnology to identify and target cancer - a lead program hits the STING pathway

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight